Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 694-876-7 | CAS number: 1345668-41-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions. Only male rats were used; no organs were weighed and there was no recovery period.
Data source
Reference
- Reference Type:
- publication
- Title:
- Petroleum hydrocarbon toxicity studies II. Animal and human response to vapours of varnish makers and painters naphtha
- Author:
- Carpenter, C. et al.
- Year:
- 1 975
- Bibliographic source:
- Toxicology and Applied Pharmacology 32: 263-281
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- yes
- Remarks:
- - Only male rats were used; no organs were weighed and there was no recovery period.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Hydrocarbons, C7-C9, n-alkanes, isoalkanes, cyclics
- EC Number:
- 920-750-0
- IUPAC Name:
- Hydrocarbons, C7-C9, n-alkanes, isoalkanes, cyclics
- Details on test material:
- - Name of test material (as cited in study report): VM&P naphtha
- Physical state: vapour
- Analytical purity: 100% pure commercial product
- Composition of test material, percentage of components: 55% paraffins, 33% cycloparaffins, 12% alkylbenzene, distributed as 48% light hydrocarbons up to C8, 26% C9, 14% C10 and higher, and 12% aromatics by mass spectrometry
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Albino Harlan-Wistar
- Sex:
- male
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: unchanged (no vehicle)
- Remarks on MMAD:
- MMAD / GSD: not applicable
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: 4 L inhalation chamber
VM&P naphtha was wholly vaporised by passage through an electrically heated vertical Pyrex tube containing a spiral groove wound with Ni-chrome wire. Resultant vapours were carried into the inhalation chamber by a counter current air stream. Desired concentrations were produced by controlling the amount of liquid vaporised into the metered air. The evaporator was designed so that mixtures were unchanged by overheating and vapour composition matched liquid composition. All chambers were operated under negative pressure. Chamber air samples, collected with airtight syringes were injected within 30 sec. after capture into a gas chromatograph; samples were taken twice a day. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysed by gas chromatography
- Duration of treatment / exposure:
- 13 weeks (65 exposure days)
- Frequency of treatment:
- 6 hours/day
5 days/week
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 2, 4, 8 mg/L
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
0, 1.3, 2.8, 5.8 mg/L (corresponding to 0, 280, 600, 1200 ppm)
Basis:
analytical conc.
- No. of animals per sex per dose:
- 25
- Control animals:
- yes, sham-exposed
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- overall appearance and behavior was checked daily.
DETAILED CLINICAL OBSERVATIONS: Yes
- overall appearance and behavior was checked daily.
BODY WEIGHT: Yes
- daily during the first week of exposure and weekly thereafter
HAEMATOLOGY: Yes
- All blood was collected from cervical vessels. Hematology included hematocrit, total erythrocyte counts, reticulocyte counts, total and differential leukocyte counts.
CLINICAL CHEMISTRY: Yes
- Parameters were serum alkaline phosphatase, SGOT, SGPT, and blood urea nitrogen.
URINALYSIS: Yes
- Urinalysis was performed on 3, 3, and 4 rats/group prior to sacrifice at weeks 3, 8 and 13 weeks, respectively.
OTHER:
Clinical pathology was performed on 3, 3, and 4 rats/group prior to sacrifice at weeks 3, 8 and 13 weeks, respectively.
Reproductive organs were not examined. - Sacrifice and pathology:
- 3 rats from each group were sacrificed for histopathologic evaluation after 3 and 8 weeks (15 and 40 actual exposure days, respectively) and all surviving rats at week 13, after 65 days of exposure.
GROSS PATHOLOGY: Yes
- Gross necropsies were performed on all rats but no organs were weighed.
HISTOPATHOLOGY: Yes
- Histopathology was performed on brain, heart, trachea, thyroid, parathyroid, liver, lung, kidney, adrenal, pituitary, spleen, duodenum, ilium, jejunum, colon, pancreas, skeletal muscle, bone marrow and sciatic nerve. - Statistics:
- Results of quantitative continuous variables (e.g. body wt changes) were evaluated using Bartlett's homogeneity of variance, analysis of variance and rank sum. Duncan's multiple range test was used if F for ANOVA was significantly high. If Bartlett's test indicated heterogeneous variances, the F-test was used for each group versus controls. If these F tests were not significant, Student's t-test was used; if significant, means were compared by Cochran t-test or rank sum test. Frequency data (e.g. mortality, micropathological conditions) were compared between groups by Chi-square with Yates correction for continuity. Critical level of significance was 0.05.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Toxic response/effects by dose level: Mortality: 2 rats in the 1.3 mg/L group died of lung abscesses and peumonia on the 9th and 65th days of exposure. These were the only deaths during the study and as these occurred at the lowest dose level only, they were considered not to be treatment-related.
BODY WEIGHT AND WEIGHT GAIN
No statistically significant (t = 0.67) variations between controls and any treated group were observed for body weight changes.
HAEMATOLOGY
5.8 mg/L group: Statistically significant increases (0.05 > p > 0.01) in neutrophils and decreased leukocyte counts were observed in rats sacrificed after 8 weeks. These effects were within normal range and were not seen in rats at 13 weeks, however a statistically significant decrease (0.05 > p > 0.01) in erythrocyte counts did occur.
CLINICAL CHEMISTRY
No statistically significant variations between controls and any treated group were observed for clinical chemistry.
GROSS PATHOLOGY
Some tubular regeneration in the kidneys of all rats (control and treated groups) was observed but was not progressive with concentration or duration of exposure to VM&P naphtha and was not considered of biological significance.
OTHER:
For animals exposed to the challenge dose of 27 mg/L, treated rats at 2.8 and 5.8 mg/L were more resistant in terms of mortality than concurrent controls or naive, untreated rats. The 2.8 mg/L rats demonstrated a statistically significant (p > 0.05) increase in "time to death".
The 1.3 mg/L group was comparable to controls.
Effect levels
- Dose descriptor:
- NOAEC
- Effect level:
- 5 800 mg/m³ air (analytical)
- Sex:
- male
- Basis for effect level:
- other: haematology: statistically significant decrease in erythrocyte counts
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Statistically significant increases in neutrophils and decreased leukocyte counts were observed in rats sacrificed after 8 weeks. These effects were within normal range and were not seen in rats at 13 weeks, however a statistically significant decrease in erythrocyte counts did occur. Therefore a NOAEC of 5.8 mg/L air (analytical concentration) was determined.
- Executive summary:
Statistically significant increases in neutrophils and decreased leukocyte counts were observed in rats sacrificed after 8 weeks. These effects were within normal range and were not seen in rats at 13 weeks, however a statistically significant decrease in erythrocyte counts did occur. Therefore a NOAEC of 5.8 mg/L air (analytical concentration) was determined.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.